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ABSTRACT 
Background 
Pulmonary arterial hypertension (PAH) is a rare disease with an emerging genetic 
basis. Heterozygous mutations in the gene encoding the bone morphogenetic protein 
receptor type 2 (BMPR2) are the commonest genetic cause of PAH, whereas biallelic 
mutations in the eukaryotic translation initiation factor 2 alpha kinase 4 gene 
(EIF2AK4) are described in pulmonary veno-occlusive disease and pulmonary 
capillary haemangiomatosis (PVOD/PCH). Here, we determined the frequency of 
these mutations and define the genotype-phenotype characteristics in a large cohort 
of patients diagnosed clinically with PAH. 
 
Methods 
Whole genome sequencing was performed on DNA from patients with idiopathic and 
heritable PAH, as well as PVOD/PCH recruited to the NIHR BioResource - Rare 
Diseases Study. Heterozygous variants in BMPR2 and biallelic EIF2AK4 variants with 
a minor allele frequency of < 1:10,000 in control data sets and predicted to be 
deleterious (by CADD, PolyPhen-2 and SIFT predictions) were identified as potentially 
causal. Phenotype data from the time of diagnosis were also captured. 
 
Results 
Eight hundred and sixty-four patients with idiopathic or heritable PAH and 16 with 
PVOD/PCH were recruited. Mutations in BMPR2 were identified in 130 patients 
(14.8%). Biallelic mutations in EIF2AK4 were identified in 5 patients with a clinical 
diagnosis of PVOD/PCH. Furthermore, 9 patients with a clinical diagnosis of PAH 
carried biallelic EIF2AK4 mutations. These patients had a reduced transfer coefficient 
for carbon monoxide (KCO: 33 [IQR: 30 - 35] % predicted) and younger age at 
diagnosis (29 [23 - 38] years) as well as more interlobular septal thickening and 
mediastinal lymphadenopathy on computed tomography of the chest, compared to 
PAH patients without EIF2AK4 mutations. However, radiological assessment alone 
could not accurately identify biallelic EIF2AK4 mutation carriers. PAH patients with 
biallelic EIF2AK4 mutations had a shorter survival. 
 
Conclusions 
Biallelic EIF2AK4 mutations are found in patients classified clinically as idiopathic and 
heritable PAH. These patients cannot be identified reliably by CT, but a low KCO and 
a young age of diagnosis suggests the underlying molecular diagnosis. Genetic testing 
can identify these misclassified patients, allowing appropriate management and early 
referral for lung transplantation. 
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CLINICAL PERSPECTIVE 
What is new? 
 1% of patients with a clinical diagnosis of PAH carry biallelic EIF2AK4 
mutations.  
 Patients diagnosed clinically with PAH who had a KCO < 50% predicted and 
age of diagnosis < 50 years were more likely to carry biallelic EIF2AK4 
mutations. The diagnostic yield for genetic testing in this group was 53%. 
 Radiological assessment was unable to distinguish reliably between these 
patients and idiopathic PAH patients.  
 Histology from these patients may show predominately pulmonary arteriopathy, 
with subtle involvement of the pulmonary veins and capillaries. 
 PAH patients with biallelic EIF2AK4 mutations had a worse prognosis 
compared to other PAH patients. 
 
What are the clinical implications? 
 Younger patients diagnosed with idiopathic PAH, but with a low KCO, have a 
high frequency of biallelic EIF2AK4 mutations. 
 Such patients should be reclassified as pulmonary veno-occlusive 
disease/pulmonary capillary haemangiomatosis (PVOD/PCH). 
 Similar to patients with PVOD/PCH these patients have a poor prognosis 
compared to other PAH patients. 
 The spectrum of radiological and histological changes associated with biallelic 
EIF2AK4 mutations is wider than previously assumed. The presence of only 
subtle or infrequent changes associated with PVOD may lead to 
misclassification of these patients as PAH. 
 Genetic testing allows early identification of these patients, facilitating 
appropriate management. 
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INTRODUCTION 
 
Pulmonary arterial hypertension (PAH) is a heterogeneous and rare disorder that can 
be classified into idiopathic and heritable forms, associated with an underlying 
condition, such as connective tissue disease or congenital heart disease, or related to 
specific drugs and toxins 1, 2. In addition, pulmonary veno-occlusive disease (PVOD) 
and pulmonary capillary haemangiomatosis (PCH) are even rarer forms of pulmonary 
hypertension that are grouped together with PAH under the current classification 
system 2.  
 
Clinical features described in patients with PVOD/PCH include a low transfer 
coefficient for carbon monoxide (KCO) and oxygen desaturation on exertion, as well 
as the presence of centrilobular ground glass opacification, interlobular septal 
thickening and mediastinal lymphadenopathy on high resolution computed 
tomography (HRCT) of the lung parenchyma 3, 4. However, these clinical and 
radiological features have also been reported in idiopathic PAH 5-7. Consequently, the 
clinical distinction between PVOD/PCH and idiopathic PAH can be challenging. It has 
been estimated that 10% of patients with PVOD/PCH are misdiagnosed as idiopathic 
PAH 8, 9. The diagnosis of PVOD/PCH is often only confirmed post mortem, or from 
explanted lungs, by histology.  
 
The histological features of PVOD/PCH typically include pulmonary venous 
obstructions and pulmonary capillary proliferation, although the distribution of these 
changes within the lung can be heterogeneous 10, 11. Pulmonary artery smooth muscle 
hypertrophy and intimal hyperplasia, similar to the changes observed in other forms of 
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PAH, may also be present. Furthermore, pulmonary venous changes have been 
reported in cases of idiopathic PAH, scleroderma-associated PAH and those with 
BMPR2 mutations, to varying extents 12, 13. 
 
A major advance in the molecular diagnosis of PVOD/PCH was the finding of biallelic 
mutations in the gene encoding the eukaryotic translation initiation factor 2 alpha 
kinase 4 (EIF2AK4) in both familial (100%) and sporadic (20-25%) cases of 
PVOD/PCH 14, 15. EIF2AK4 is an activator of the integrated stress response (ISR) 
pathway, and responds to environmental stresses, including amino acid deprivation, 
by phosphorylating the alpha subunit of eukaryotic translation initiation factor 2 11, 16, 
17. These discoveries suggest that EIF2AK4 mutations are specific to PVOD/PCH and 
that finding biallelic EIF2AK4 mutations in a patient with pulmonary hypertension 
would be diagnostic of PVOD/PCH. Patients with PVOD/PCH have a poor prognosis 
and risk fatal pulmonary oedema with the use of pulmonary artery vasodilator 
therapies 4, 18-20. Consequently, early and accurate diagnosis is vital to guide clinical 
management.  
 
Heterozygous mutations in the gene encoding the bone morphogenetic protein type 2 
receptor (BMPR2) are the most common genetic cause of PAH. They are found in 
approximately 17% of individuals with idiopathic PAH and 82% with a family history of 
the disease 21. However, mutations in BMPR2 have also been reported in patients with 
histologically proven PVOD 4, 22-24. Thus, there remains considerable uncertainty to 
what extent the finding of EIF2AK4 or BMPR2 mutations reliably predict the clinical 
phenotype and response to therapy in a population of patients with PAH.  
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Here we report the genetic and phenotypic characteristics of patients assessed for 
BMPR2 and EIF2AK4 mutations, through whole genome sequencing, within a large 
cohort (n=880) of PAH patients recruited to the National Institute of Health Research 
(NIHR) BioResource – Rare Diseases (BRIDGE) Study (Supplementary Table 1). The 
frequency of mutations in other previously reported genes associated with PAH will be 
reported in a future publication. In this study, we identified and characterised patients 
with a clinical and radiological diagnosis of idiopathic PAH who were found to possess 
biallelic EIF2AK4 mutations. These patients had a low KCO and were diagnosed at a 
younger age compared with idiopathic PAH patients without mutations in these genes. 
We show that, in common with patients diagnosed clinically with PVOD/PCH, PAH 
patients with biallelic EIF2AK4 mutations have a shorter survival. We conclude that 
clinical assessment alone is inadequate for the accurate diagnosis of PVOD/PCH. 
Clinical genetic testing in younger patients presenting clinically with PAH but with a 
low KCO, will allow appropriate classification, leading to better risk stratification and 
management of these patients.  
 
METHODS 
 
Ethical approval and consent 
UK patients (621 [70.6%]) were recruited prospectively to the BRIDGE Study and 
provided written informed consent for genetic analysis and the capture of clinical data 
(NIHR BioResource - Rare Diseases Study 13/EE/0325). The cohort also included 
patients recruited retrospectively from non-UK centres (191 [21.7%]), and deceased 
UK patients (68 [7.7%]), if they had signed local tissue bank consent forms allowing 
genetic sequencing. 
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Explanted lung tissue from an individual undergoing lung transplantation for end stage 
PAH was collected under Papworth Hospital Research Tissue Bank ethics 
(08/H0304/56). 
 
Recruitment and patients 
The BRIDGE Study is a prospective study recruiting both prevalent and incident 
patients with selected rare diseases. Recruitment to the BRIDGE PAH Study started 
in January 2013 and the last patient included in this analysis was recruited on 
15/06/2016. Patients with idiopathic PAH, heritable PAH, PVOD and PCH, diagnosed 
according to international guidelines at specialist pulmonary hypertension centres in 
the United Kingdom, Netherlands and France, were recruited (Figure 1 and 
Supplementary Table 2) 2. This included 14 patients with confirmed mutations in 
BMPR2.  
 
Throughout the manuscript, we classify patients recruited to the study as idiopathic 
PAH or familial PAH based on the absence or presence of a family history of the 
disease. The term heritable PAH does not distinguish between sporadic PAH patients 
with mutations, and patients with a mutation where there is a family history. Therefore, 
the term “heritable PAH” is only used when referring to previous publications and 
guidelines. 
 
Patients with other rare diseases and their unaffected relatives recruited to the 
BRIDGE Study (Supplementary Table 3) acted as non-PAH controls for the genetic 
analysis.  
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Whole genome sequencing and variant calling 
Next generation sequencing using 100-150 base pair paired-end sequencing was 
performed on DNA libraries created from genomic DNA using Illumina HiSeq 2500 
and HiSeq X (Illumina Inc, San Diego, USA). 
 
Reads were aligned against the Genome Reference Consortium human genome 
(build 37) (GRCh37) and variants were called using the Issac Aligner and Variant 
Caller respectively (version 2, Illumina Inc.). Variants in BMPR2 and EIF2AK4 were 
extracted and annotated using Ensembl’s Variant Effect Predictor (VEP) v84 25. 
Deletions (resulting in the loss of more than 50bp) were identified by applying Isaac 
Copy Number Variant Caller (Canvas, Illumina) and Isaac Structural Variant Caller 
(Manta, Illumina). Further information is provided in the supplemental materials. 
 
Likely causal variants were identified based on minor allele frequency (MAF) and 
predicted deleteriousness. Variants were considered further if they had a MAF of less 
than 1 in 10,000 in unrelated non-PAH BRIDGE controls and the ExAC database 26. 
The rare variants that passed the MAF filtering were then assessed for 
deleteriousness. Variants were considered pathogenic based on a combined 
annotation dependent depletion (CADD) score of 15 or higher and PolyPhen-2 or SIFT 
predictions not classified as “benign” or “tolerated” respectively 27-29. 
 
Over-representation analyses 
For comparison of variant frequencies between disease and control groups only 
variants from unrelated individuals were used. The PRIMUS software package was 
used to identify non-related individuals amongst both non-PAH BRIDGE controls and 
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PAH patients 30. The number of unrelated control subjects was maximised by including 
either patients with other rare diseases or their unaffected relatives. The frequency of 
rare and predicted deleterious heterozygous EIF2AK4 variants in PAH index cases 
was also compared to publically available information in the ExAC database 
(http://exac.broadinstitute.org) 26. This analysis provides the maximum estimate of the 
frequency of heterozygous EIF2AK4 variants in the ExAC database as variants in 
ExAC were assumed not to be in a compound heterozygous state.  
 
Phenotypic data capture and CT assessment 
Paper and electronic patient records of PAH patients were reviewed to capture 
demographic and phenotypic variables from the time of diagnosis and follow up. 
Survival data for UK patients were obtained from recruiting centres through the NHS 
National Spine and local databases. Anonymised information was captured securely 
online using the free OpenClinica software, adapted for data capture specific to PAH.  
 
CT images of the chest, where available, were reviewed independently by 2 
cardiothoracic radiologists (AS and NS), with specialist imaging experience in 
pulmonary hypertension, blinded to the underlying diagnoses using a customised 
proforma. Further information is provided in the supplemental materials, 
Supplementary Table 4 and Supplementary Table 5. 
 
Statistical analysis 
Statistical analysis was performed in R (www.r-project.org). Further information is 
provided in the supplemental materials. 
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Semi-parametric Cox-proportional hazard models were used to assess survival 
between groups using the “survival” package in R. Time from diagnosis to both death 
and death or transplantation was assessed. Age at diagnosis and gender were used 
as covariates in the models. Further information is provided in the supplemental 
materials. 
 
RESULTS 
 
Study patients  
Whole genome sequencing was performed on 932 patients recruited to the NIHR 
BRIDGE PAH Study and 7134 non-PAH control subjects recruited to other NIHR 
BRIDGE Study cohorts. Fifty-two patients were excluded from further analysis 
because they did not have a clinical diagnosis of idiopathic PAH, heritable PAH, PVOD 
or PCH  (Figure 1). The remaining 880 patients (of which 872 were defined as 
unrelated index cases) consisted of 16 patients (1.8%) with a clinical diagnosis of 
PVOD/PCH, 56 (6.4%) with PAH and a family history of the disease (referred to as 
familial PAH) and 808 (91.8%) with idiopathic PAH and no known family history. One 
of the 16 patients with a clinical diagnosis of PVOD/PCH had an affected sister, 
whereas the remainder had the sporadic form of the disease. 
 
BMPR2 mutations in the PAH cohort 
Rare and predicted deleterious BMPR2 mutations (single nucleotide variants, indels 
and larger deletions) were found in 41 patients (73.2%) with familial PAH and 89 
patients (11.0%) with idiopathic PAH. No BMPR2 mutations were found in patients 
with a clinical diagnosis of PVOD/PCH. 
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Rare and predicted deleterious EIF2AK4 variants in the PAH cohort 
Sixty-nine rare and predicted deleterious EIF2AK4 single nucleotide variants and 
indels were present in the NIHR BRIDGE Study. No large deletions were found that 
affected the EIF2AK4 gene locus. The variants are summarised in Supplementary 
Table 6. Five of the 16 patients (31.3%) with clinically diagnosed PVOD/PCH carried 
biallelic EIF2AK4 mutations (2 homozygotes and 3 compound heterozygotes).  
 
Twenty-five EIF2AK4 variants were also found in 19 patients (2.2%) diagnosed 
clinically with PAH, in whom there was no clinical diagnosis of PVOD/PCH (5 
homozygotes, 4 compound heterozygotes and 10 heterozygotes; Supplementary 
Table 7). One of these patients with a homozygous EIF2AK4 mutation (c.3097C>T 
creating a premature stop codon) had a sister who had died of PAH. There was no 
reported family history of PVOD/PCH.  
 
The remaining rare EIF2AK4 variants were found in a heterozygous state in 36 control 
subjects (0.5%). Four of these variants appeared in more than 1 non-PAH control 
subject and none were shared with PAH patients. 
 
Over-representation of rare heterozygous EIF2AK4 variants in idiopathic PAH patients 
compared to control subjects 
The proportion of patients with a clinical diagnosis of idiopathic PAH carrying 
heterozygous rare EIF2AK4 variants (1.2%) was significantly greater than the non-
PAH control subjects (0.5%; p = 0.030). A similar over-representation in idiopathic 
PAH patients was observed when compared to allele frequencies in the ExAC 
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database (0.6%; p = 0.042). Two idiopathic PAH patients with heterozygous rare 
EIF2AK4 variants also carried a rare and predicted deleterious BMPR2 mutation. 
 
Phenotype of patients with a clinical diagnosis of PAH and biallelic EIF2AK4 mutations  
Patients with a clinical diagnosis of PAH and biallelic EIF2AK4 mutations presented at 
a younger age (median [IQR]: 29 [23 - 38] years) compared to patients without these 
variants (51 [37 - 65] years; p = 0.024) (Table 1). Mean pulmonary artery pressure, 
cardiac output and pulmonary vascular resistance were not significantly different 
between PAH patients with biallelic EIF2AK4 mutations and the other groups. As 
previously reported, haemodynamic variables were significantly more severe in 
patients with BMPR2 mutations compared to those without any mutations in these 
genes.  
 
The PAH patients with biallelic EIF2AK4 mutations exhibited a reduced KCO (33 [30 - 
35] % predicted) compared to BMPR2 mutation carriers (81 [73 - 92] % predicted, p < 
0.001) and PAH patients with no identified mutation (71 [51 - 85] % predicted, p = 
0.001). PAH patients with biallelic EIF2AK4 mutations had no obstructive or restrictive 
deficit on spirometry. These differences remained after exclusion of patients with 
abnormal spirometry in the other groups (FEV1 < 80% or FVC < 80%) (Supplementary 
Table 8).  
 
Digital clubbing was over-represented amongst patients with biallelic EIF2AK4 
mutations diagnosed clinically with PAH (42%; p=0.002).  Eleven percent of patients 
with a clinical diagnosis of PVOD were clubbed. 
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Only one patient with a heterozygous rare and predicted deleterious EIF2AK4 variant 
(c.2516T>C) had a reduced KCO (54% predicted) with normal spirometry (FEV1 102% 
predicted, FVC 98% predicted and TLC 100% predicted). Although, there was mild 
paraseptal emphysema on thoracic CT (< 5% of the lung parenchyma affected). This 
patient, a 44-year-old Caucasian male diagnosed with idiopathic PAH, also carried a 
rare and deleterious BMPR2 splice acceptor mutation (c.853-2A>G).  
 
We questioned whether KCO was a predictor of biallelic EIF2AK4 mutations in the 
wider cohort. However, amongst PAH patients with no mutations and normal 
spirometry (n=255), a reduced KCO (< 50% predicted) was present in 65 patients 
(25.5%). In these patients with a reduced KCO and preserved spirometry, 90.8% were 
aged over 50 years at diagnosis and 69.2% had a history of coronary artery disease, 
left ventricular dysfunction or cardiovascular risk factors (diabetes mellitus, systemic 
hypertension or hyperlipidaemia).  
 
Given the high prevalence of a low KCO with preserved spirometry in the wider cohort, 
we restricted an analysis to patients under the age of 50 years, who at the time of 
diagnosis had normal spirometry (n=164). Even, in this group a significant proportion 
(15, 9.1%) had a KCO < 50% predicted (Figure 2). Eight of these 15 patients carried 
biallelic EIF2AK4 mutations. One patient with biallelic EIF2AK4 mutations was aged 
70 years at diagnosis and subsequently did not meet this cut-off.  
 
Amongst patients with normal spirometry, the presence of a KCO < 50% predicted and 
age at diagnosis < 50 years had a high sensitivity (0.889) and specificity (0.977) for 
identifying patients who carry biallelic EIF2AK4 mutations, the positive predictive value 
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was low (0.533). Nevertheless, in terms of the diagnostic yield, while genetic testing 
for biallelic EIF2AK4 mutations in the entire cohort of patients diagnosed clinically with 
PAH yielded a 1% detection rate, the presence of biallelic EIF2AK4 mutations in PAH 
patients with a KCO < 50% with normal spirometry and aged under 50 at diagnosis 
was 53%.   
 
CT features of EIF2AK4 mutation carriers 
Centrilobular ground glass opacification extent, mediastinal lymphadenopathy and 
interlobular septal thickening are considered suggestive of PVOD/PCH. However, we 
found subtle or gross centrilobular ground glass opacification in 38% of patients 
diagnosed clinically with PAH and carrying no mutations (n=21) and 67% of PAH 
patients with BMPR2 mutations (n=21). This was not significantly different compared 
to patients with a clinical diagnosis of PAH and biallelic EIF2AK4 mutations (86%, n=7) 
and patients with a clinical diagnosis of PVOD (50%, n=14). Gross interlobular septal 
thickening and mediastinal lymphadenopathy was significantly more frequent amongst 
patients with PAH and biallelic EIF2AK4 mutations (29% and 57% respectively) and 
those with PVOD (64% and 79%) compared to patients with PAH and no mutation (5% 
and 0%) or BMPR2 mutations (5% and 10%). A radiological suspicion of PVOD/PCH 
was raised in 71% of those with PVOD, 57% of patients with a clinical diagnosis of 
PAH and biallelic EIF2AK4 mutations, 14% of PAH patients with no mutation, and 5% 
of those with BMPR2 mutations (Table 2).  
 
A further CT analysis comparing patients with biallelic EIF2AK4 mutations (with a 
clinical diagnosis of PVOD/PCH or PAH; n=11) and those with a clinical diagnosis of 
PVOD but not carrying biallelic EIF2AK4 mutations (n=10) was made (Supplementary 
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Table 9). Patients with biallelic EIF2AK4 mutations were younger at diagnosis (27 
[IQR: 23 - 34] years) compared to those with PVOD and no EIF2AK4 mutations (68 
[64 - 72] years, p=0.001). The patients with biallelic EIF2AK4 mutations also had a 
lower KCO (32 [29 – 33] % predicted) compared to patients with PVOD and no 
EIF2AK4 mutations (41.4 [37 – 54] % predicted, p=0.013). Centrilobular ground glass 
opacification appeared more extensive in those with biallelic EIF2AK4 mutations 
(82%) compared to those without a mutation (10%; p=0.012). However, pleural 
effusions were more common amongst those without a mutation (40%) compared to 
patients with biallelic EIF2AK4 mutations (0%, p=0.035). This may suggest that 
patients with biallelic EIF2AK4 mutations have a distinct radiological phenotype 
compared to patients with PVOD and no biallelic EIF2AK4 mutations. 
  
Response to pulmonary artery vasodilator therapies 
The response to pulmonary artery vasodilator therapies at 1 and 3 years was 
assessed for patients with a clinical diagnosis of PAH and biallelic EIF2AK4 mutations 
as well as the other PAH patients included in the CT analysis.  Patients with a clinical 
diagnosis of PAH and biallelic EIF2AK4 mutations did not improve their functional 
class at either 1 year or 3 years post diagnosis unlike the other PAH groups 
(Supplementary Table 10).   
 
Histological features of biallelic EIF2AK4 mutation carrier 
The explanted lungs of one patient diagnosed with idiopathic PAH but found to have 
a homozygous EIF2AK4 missense mutation (c.1795G>C, p.G599R) were assessed. 
The predominant histological feature was pulmonary arterial vasculopathy. The 
pulmonary arteries predominantly showed concentric and eccentric intimal fibrosis. No 
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plexiform lesions were observed. Although infrequent, there was some fibrosis of the 
septal veins and venules, some of which were nearly completely occluded. Although 
there was evidence of capillary congestion, no capillary hemangiomatosis was 
observed (Figure 3). The missense variant carried by this patient was not reported in 
the ExAC database, occurs in a conserved area of the genome (GERP score 5.5) and 
was predicted to be deleterious (CADD score 32, PolyPhen-2 prediction of “probably 
damaging [1]”, SIFT prediction of “deleterious [0]”). The same homozygous mutation 
was also found in a second unrelated patient with a clinical diagnosis of idiopathic 
PAH. 
 
Impact of genotype on survival 
Eight hundred and fifty-eight patients were included in the Cox proportional hazards 
model (Supplementary Table 11, Supplemental Figure 1). Patients diagnosed 
clinically as PAH with biallelic EIF2AK4 mutations had a shorter survival time from 
diagnosis compared to the BMPR2 mutation carriers (p < 0.001) and those without 
any variants in PAH associated genes (p < 0.001). Age (p < 0.001) and gender (p = 
0.001) also had a significant effect on survival, with male sex and an older age at 
diagnosis associated with shorter survival in the model. Similar results were obtained 
when assessing the time to death or transplantation (Supplementary Tables 12). 
 
DISCUSSION 
 
This is the first study to analyse the frequency of EIF2AK4 rare variation in a large 
cohort of PAH patients and make detailed phenotypic and radiological assessments. 
Previously the presence of biallelic EIF2AK4 mutations were reported in patients with 
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a clear clinical diagnosis of PVOD/PCH as well as a large kindred and a single family 
with a possible diagnosis of PAH 20, 31, 32. As expected, we identified a high frequency 
of EIF2AK4 biallelic mutations in patients with a clear clinical presentation of 
PVOD/PCH. However, we also found biallelic EIF2AK4 mutations in patients with a 
clinical diagnosis of PAH. 
 
The discovery of EIF2AK4 mutations in PVOD/PCH raised the possibility of rapid 
molecular diagnosis in the majority of patients with familial, and up to 25% of patients 
with sporadic PVOD/PCH 14, 15. In the present study, the presence of biallelic EIF2AK4 
mutations was associated with a poor prognosis, even in patients who have a clinical 
diagnosis of PAH, and who did not develop pulmonary oedema in response to 
pulmonary artery vasodilator therapies. Therefore, early identification of these patients 
through genetic testing may prompt early referral for lung transplantation similar to 
patients with clinically diagnosed PVOD/PCH 18.  
 
The presence of biallelic EIF2AK4 mutations in patients with a clinical diagnosis of 
PAH raises the question whether EIF2AK4 mutations can cause classical idiopathic 
PAH, or whether there are cases of PVOD/PCH caused by EIF2AK4 mutations that 
are wrongly classified even by expert centres. We further show that phenotypic, 
radiological and histological assessments can be difficult to interpret. The presence of 
subtle or infrequent features may lead to an incorrect diagnosis of PAH in patients with 
biallelic EIF2AK4 mutations. This study suggests that patients with pathogenic biallelic 
EIF2AK4 mutations may present with a spectrum of phenotypic, radiological and 
histological features that can overlap with PAH.  
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PAH patients with biallelic EIF2AK4 mutations demonstrated a reduced KCO despite 
normal spirometry, which is characteristic of patients with PVOD/PCH. The reduced 
KCO likely reflects widespread reduction in alveolar gas exchange due to endothelial 
proliferation and patchy thickening of the blood gas barrier by the process of capillary 
haemangiomatosis. Ultrastructural thickening of the capillary basement membrane 
may also play a role 33. In keeping with previous reports in PVOD/PCH we also show 
that PAH patients with biallelic mutations in EIF2AK4 are younger at diagnosis than 
patients with either BMPR2 mutations or no known mutation 14, 20. However, the 
presence of these characteristic features has a low positive predictive value for the 
identification of patients with biallelic EIF2AK4 mutations.  
 
In contrast to previous descriptions of patients with PVOD, none of the patients with 
clinically diagnosed PAH and biallelic EIF2AK4 mutations developed pulmonary 
oedema in response to pulmonary artery vasodilator therapies. For example, 
intravenous prostanoids were used in 50% of these patients. In classical PVOD 
patients, pulmonary oedema with intravenous prostanoids has been reported in up to 
44% of patients after a median treatment duration of just 9 days 4. Presumably the 
extent and severity of the pulmonary venous involvement in these patients might 
underlie the differing responses to prostanoids. 
 
It is generally considered that HRCT imaging is a useful non-invasive test to assist in 
the diagnosis of suspected PVOD/PCH 11. Although there was an increased 
prevalence of mediastinal lymphadenopathy and interlobular septal thickening in PAH 
patients with biallelic EIF2AK4 mutations, we found that radiological features at the 
time of diagnosis could not accurately determine the underlying genotype 6. The 
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differing radiological features of all patients with biallelic EIF2AK4 mutations compared 
with PVOD cases without mutations is of interest. This may reflect differences between 
the younger onset genetic cases of PVOD, compared with the predominantly older 
group of patients without EIF2AK4 mutations in whom other non-genetic factors, such 
as exposure to inorganic solvents, may play an important role 34. 
 
Histological examination (usually post mortem or from explanted lungs) is often 
considered essential for diagnostic confirmation of PVOD/PCH but may be 
confounded by the heterogeneous nature of vascular pathology 35. Surgical biopsy of 
the lung in patients with severe PAH is contraindicated and a limitation of this study is 
that lung tissue from only one patient with biallelic EIF2AK4 mutations was available 
for analysis. This patient had a rare and predicted deleterious homozygous missense 
mutation in EIF2AK4. The predominant feature on assessment of the explanted lung 
tissue was of pulmonary arteriopathy, as usually seen in PAH. Although only 
infrequent, fibrosis of the septal venules and the possible presence of siderophages 
in the alveolar space were observed. These features are found in patients with 
PVOD/PCH. This case supports the hypothesis that patients with biallelic EIF2AK4 
mutations may present with a spectrum of venous and arterial involvement. 
 
There are increasing reports of phenotypic, radiological and histological similarities 
between PAH and PVOD/PCH 6, 12, 13. Tenorio et al. reported a homozygous missense 
mutation in EIF2AK4 in a large kindred of Iberian Romani with apparent heritable PAH 
31. This kindred is likely to have PVOD/PCH as these diagnoses were not confirmed 
histologically and PVOD was suspected in half the patients. More recently, Best et al. 
also report two sisters with apparent heritable PAH carrying biallelic EIF2AK4 
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mutations 32. These patients also had a reduced KCO but had not had HRCT 
assessment of their lung parenchyma which may have altered their clinical diagnosis. 
Taken together, these previous reports are compatible with the findings in this larger 
cohort, that patients with a clinical presentation of idiopathic or heritable PAH may in 
fact have underlying PVOD/PCH as determined by genetic analysis. 
 
A strength of this study is the centralised reporting of radiographic features. However, 
the data collection was retrospective and incomplete in some cases. Assessing rare 
diseases, such as PAH and PVOD/PCH, with a prospective study recruiting incident 
cases would take a prohibitively long time. This is especially true when assessing 
survival and response to therapy. In this study, we demonstrated a worse prognosis 
in patients with a clinical diagnosis of PAH and biallelic EIF2AK4. However, further 
studies of survival and response to thepray will be needed to definitively show whether 
“misclassified” PAH patients with biallelic EIF2AK4 mutations have a similarly poor 
prognosis as classical PVOD patients with these mutations. 
 
The genetic architecture of idiopathic and heritable PAH remains to be fully elucidated. 
Ongoing analysis of whole genome sequence data in our cohort is likely to reveal 
novel rare variation underlying this condition. Mutations in BMPR2 account for 
approximately 17% of idiopathic PAH patients and other known PAH genes account 
for approximately 1-2% of all cases 21, 36. In the present study BMPR2 mutations were 
found in 11% of patients without a family history of PAH. It is worth noting that patients 
with the sporadic form of the disease with no reported family history represent a higher 
burden of BMPR2 mutations (n=89) compared to those with a family history (n=49). 
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This has important implications for clinical genetic testing in patients with sporadic as 
well as familial disease. 
 
In previous studies mutations in both EIF2AK4 alleles are required to cause PVOD 
and PCH 14, 15. In autosomal recessive disorders, it is unusual for the heterozygous 
state to manifest the disease phenotype and thus heterozygous EIF2AK4 variants 
would not be expected to be pathogenic. In this study, we found a significant over-
representation of heterozygous rare and predicted deleterious EIF2AK4 variants in 
PAH compared to control subjects and report 2 patients with rare variants in both 
BMPR2 and EIF2AK4. Recently, the possibility that heterozygous EIF2AK4 variants 
influence the penetrance of BMPR2 mutations has been raised in a single family with 
PAH 37. Further studies are required to determine whether heterozygous EIF2AK4 
variants contribute to aetiology in PAH. 
 
In summary, we demonstrate that biallelic EIF2AK4 mutations are found in patients 
diagnosed clinically with idiopathic and familial PAH. These patients may have subtle 
features suggestive of PVOD/PCH on close inspection and are likely to have 
underlying PVOD/PCH. The spectrum of phenotypic, radiological and histological 
features found in patients with biallelic EIF2AK4 mutations made by current clinical 
assessments is wider and less clear cut than previously recognised.  This may lead to 
misclassification of patients as PAH rather than PVOD and hinders accurate risk 
stratification. Ascertaining the EIF2AK4 mutation status of patients through clinical 
genetic testing provides additional information to aid risk stratification and guide 
management. In a young patient presenting with apparent PAH, the presence of a low 
KCO with normal spirometry strongly suggests the presence of underlying biallelic 
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EIF2AK4 mutations. Patients with an apparent clinical diagnosis of PAH and biallelic 
EIF2AK4 mutations have a worse prognosis compared to patients with BMPR2 
mutations and those without these mutations. Clinical genetic testing should aid 
identification of this high-risk group and facilitate early referral for lung transplantation 
and appropriate management.  
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Figure legends 
Figure 1.  Subjects recruited to the NIHR BioResource – Rare Diseases Study 
and the clinical diagnostic categories of PAH patients included in this study. 
 
Figure 2. The transfer coefficient for carbon monoxide (KCO) is influenced by 
genotype in pulmonary arterial hypertension. Patients with FEV1 < 80 % predicted 
and FVC < 80 % predicted and diagnosed with PAH or PVOD/PCH after 50 years of 
age excluded from the plot. 
 
Figure 3. Representative histopathological images from one patient with 
clinically diagnosed idiopathic PAH but found to have a rare (not reported in the 
ExAC database) and predicted deleterious (CADD score 32) homozygous 
EIF2AK4 missense variant (c.1795G>C). The patient was of Pakistani origin and did 
not have a family history of PAH or PVOD. At presentation, he was 22 years old and 
had a reduced KCO (31% predicted) despite preserved spirometry. HRCT of his chest 
showed subtle but extensive (50-75% involvement) ground glass opacification. No 
interlobular septal thickening or mediastinal lymphadenopathy was observed. No 
suspicion of PVOD/PCH was raised based on radiological appearances. 
 
Histopathology was reviewed by two independent pathologists each confirming the 
predominant histological pattern to be one of pulmonary arterial vasculopathy. The 
pulmonary arteries showed eccentric and concentric intimal fibrosis and medial 
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hypertrophy (A, B) as well as some lesions with features of recanalised thrombus (C). 
Several concentrically muscularised arterioles were also observed (D). No complex 
plexiform lesions were present. There was patchy thickening of the alveolar septa with 
capillary congestion and pigmented intra-alveolar macrophages similar to PCH (E, F). 
Venous remodelling was difficult to trace and infrequent, but present. Fibrous 
thickening of the intima in septal veins (G, I) and a micro-vessel (H). 
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Tables 
 
PAH patients with 
BMPR2 mutations * 
PAH patients with 
no mutations in 
PAH associated 
genes 
PAH patients with 
EIF2AK4 
heterozygous 
variants 
PAH patients with 
biallelic EIF2AK4 
mutations 
PVOD/PCH 
patients 
p 
n 130 704 8 9 16  
Age (years) 39 [31 - 52] 51 [37 - 65] 49 [36 - 67] 29 [23 - 38] 57 [41 - 69] <0.001 
Gender (n female [%]) 85 [65.4%] 494 [70.2%] 7 [87.5%] 4 [44.4%] 9 [56.2%] 0.18 
Ethnicity (n white Caucasian 
[%]) 
108 [83.1%] 551 [78.5%] 5 [62.5%] 2 [22.2%] 13 [81.2%] 0.002 
Digital clubbing 
(n [%]) 
6 [9.7%] 10 [3.4%] 0 [0%] 3 [42.9%] 1 [11.1%] 0.002 
BMI 28 [24 - 33] 28 [24 - 33] 26 [23 - 28] 24 [20 - 27] 27 [24 - 31] 0.216 
mPAP (mmHg) 57 [51 - 69] 52 [44 - 61] 44 [42 - 52] 52 [46 - 65] 48 [40 - 58] <0.001 
CO (L/min) 3 [3 - 4] 4 [3 - 5] 3 [3 - 5] 5 [3 - 6] 4 [3 - 4] <0.001 
PVR (WU) 15 [11 - 20] 10 [7 - 14] 9 [6 - 10] 9 [8 - 13] 10 [9 - 12] <0.001 
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Vasoresponders (n [%]) 0 [0%] 28 [17.5%] 0 [0%] 0 [0%] 0 [0%] 0.011 
FEV1 (%pred) 90 [78 - 99] 84 [72 - 95] 83 [71 - 94] 94 [85 - 100] 85 [70 - 95] 0.031 
FVC (%pred) 97 [86 - 109] 95 [82 - 106] 96 [75 - 98] 100 [86 - 119] 97 [81 - 103] 0.310 
KCO (%pred) 81 [73 - 92] 71 [51 - 85] 81 [72 - 95] 33 [30 - 35] 37 [32 - 47] <0.001 
Resting SAO2 (%) 96 [94 - 97] 96 [93 - 97] 98 [98 - 98] 91 [90 - 94] 94 [91 - 95] 0.010 
SAO2 post walk test (%) 94 [90 - 97] 92 [85 - 96] 94 [84 - 96] 78 [75 - 82] 88 [85 - 89] <0.001 
Table 1. Phenotypic summary of EIF2AK4 variant carriers. Patients with a clinical diagnosis of PAH and biallelic EIF2AK4 mutations are younger at diagnosis 
and have a significantly reduced KCO compared to other groups. 
BMI - body mass index, mPAP - mean pulmonary artery pressure, PVR - pulmonary vascular resistance, FEV1 - forced expiratory volume in 1 second, FVC - 
forced vital capacity, KCO - transfer coefficient for carbon monoxide. * Also includes the 2 patients with a heterozygous EIF2AK4 variant and a BMPR2 variant. 
Data presented as median [IQR] unless indicated. Percentages were calculated using the number of patients for whom data were available as the denominator.  
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 Group 
PAH patients 
with BMPR2 
mutations 
PAH patients 
with no 
mutations in 
the previously 
reported PAH 
genes 
PAH patients 
with 
heterozygous 
EIF2AK4 
variants 
PAH patients 
with biallelic 
EIF2AK4 
mutations 
PVOD p 
 n 21 21 4 7 14  
Centrilobular ground 
glass opacification 
density 
None 7 [33.3%] 13 [61.9%] 2 [50.0%] 1 [14.3%] 7 [50.0%] 
0.122 Subtle 12 [57.1%] 5 [23.8%] 0 [0.0%] 2 [28.6%] 3 [21.4%] 
Present 2 [9.5%] 3 [14.3%] 2 [50.0%] 4 [57.1%] 4 [28.6%] 
Centrilobular ground 
glass opacification 
extent 
None 8 [38.1%] 13 [61.9%] 2 [50.0%] 1 [4.3%] 8 [57.1%] 
0.077 
<5% 0 [0.0%] 3 [14.3%] 0 [0.0%] 1 [14.3%] 1 [7.1%] 
5-25% 2 [9.5%] 0 [0.0%] 1 [25.0%] 2 [28.6%] 1 [7.1%] 
25-50% 2 [9.5%] 4 [19.0%] 0 [0.0%] 0 [0.0%] 2 [14.3%] 
50-75% 5 [23.8%] 1 [4.8%] 0 [0.0%] 2 [28.6%] 0 [0.0%] 
75-100% 4 [19.0%] 0 [0.0%] 1 [25.0%] 1 [14.3%] 2 [14.3%] 
None 17 [81.0%] 18 [85.7%] 4 [100.0%] 5 [71.4%] 4 [28.6%] 0.001 
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Interlobular septal 
thickening 
Subtle 3 [14.3%] 2 [9.5%] 0 [0.0%] 0 [0.0%] 1 [7.1%] 
Present 1 [4.8%] 1 [4.8%] 0 [0.0%] 2 [28.6%] 9 [64.3%] 
Mediastinal 
lymphadenopathy 
None 19 [90.5%] 21 [100.0%] 4 [100.0%] 3 [42.9%] 3 [21.4%] 
<0.001 
Present 2 [9.5%] 0 [0.0%] 0 [0.0%] 4 [57.1%] 11 [78.6%] 
Pleural effusion 
None 17 [81.0%] 21 [100.0%] 3 [75.0%] 7 [100.0%] 10 [71.4%] 
0.048 
Small 4 [19.0%] 0 [0.0%] 1 [25.0%] 9 [0.0%] 4 [28.6%] 
Neovascularity 
None 12 [57.1%] 18 [85.7%] 4 [100.0%] 6 [85.7%] 13 [92.9%] 
0.077 
Present 9 [42.9%] 3 [14.3%] 0 [0.0%] 1 [14.3%] 1 [7.1%] 
CT diagnosis 
PAH 20 [95.2%] 18 [85.7%] 3 [75.0%] 3 [42.9%] 4 [28.6%] 
 Possible 
PVOD/PCH 
1 [4.8%] 3 [14.3%] 1 [25.0%] 4 [57.1%] 10 [71.4%] 
Table 2. Radiological features and consensus radiological diagnosis of PAH patients in the CT substudy. Data presented as n [%]. 
 
